TAKHZYRO
PeakmAblanadelumab-flyo
BLASUBCUTANEOUSSOLUTIONPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
TAKHZYRO (lanadelumab-flyo) is kallikrein inhibitors [moa]. First approved in 2018.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAKHZYRO (lanadelumab-flyo) is a monoclonal antibody that inhibits plasma kallikrein, a key enzyme in the bradykinin-mediated inflammation cascade. It is indicated for the treatment of hereditary angioedema (HAE) in patients with C1-esterase inhibitor deficiency or dysfunction. The drug works by blocking kallikrein-driven bradykinin production, preventing acute angioedema attacks.
$6MPart D
PeakPeak lifecycle with modest Part D engagement ($6M, 147 claims in 2023) suggests a niche HAE market with stable but limited patient volume requiring specialized commercial infrastructure.
Mechanism of Action
Kallikrein Inhibitors
Pharmacologic Class:
Plasma Kallikrein Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
Started Jul 2026
35 enrolled
Hereditary Angioedema (HAE)
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
Started Jul 2024
115 enrolled
Hereditary Angioedema (HAE)
Career Relevance
Zero linked job postings indicate this is a stable, mature product with a small dedicated team in a niche indication. Career roles focus on HAE specialty marketing, medical affairs, and patient support infrastructure rather than high-volume commercial expansion.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.